Inflammation

Patients with comorbid chronic rhinosinusitis (CRS) with nasal polyps and severe asthma reported significant improvement in their sense of smell when treated with the biologics omalizumab, mepolizumab, reslizumab, or benralizumab, with no significant differences observed between the treatment groups.

A recent study sought to address what is known about proton pump inhibitors (PPIs) as a therapy for eosinophilic esophagitis and long-term outcomes in patients who respond to them as a way to guide treatment decisions.

Katharine Rimes, PharmD, and John Bosso, MD, discussed updates in management of chronic rhinosinusitis with nasal polyps at the 2022 Asembia Specialty Pharmacy Summit.

A machine learning approach identified age and several comorbidities, such as nasal polyps and asthma, as being associated with revision endoscopic sinus surgery among patients with chronic rhinosinusitis.

The authors said that to their knowledge, this is the first report of cytomegalovirus (CMV) that developed during the treatment of eosinophilic enteritis in an adult.

Patients with aspirin-exacerbated respiratory disease (AERD) who initiated treatment with dupilumab as an add-on asthma or chronic rhinosinusitis with nasal polyps therapy reported rapid clinical improvement that was sustained after 3 months.

Presence of human papillomavirus (HPV) was significantly associated with incidence of chronic rhinosinusitis with nasal polyps (CRSwNP), although no differences in disease severity were observed among HPV-positive and HPV-negative patients with CRSwNP.

A small retrospective study examined outcomes in patients with eosinophilic esophagitis (EoE) who did respond to solo therapies.

Use of dupilumab was associated with significant improvement in clinical symptoms of chronic rhinosinusitis (CRS) with nasal polyps among real-world patients in Canada, with benefits shown to be similar to that observed in randomized clinical trials.

Patients with chronic rhinosinusitis (CRS) with nasal polyps identified several unmet needs regarding their condition, particularly a lack of public and physician awareness on disease burden and poor sleep quality.

An exhalation system with fluticasone was shown to significantly reduce nasal polyp score at 4 and 16 weeks compared with placebo, with improvements also observed in several patient-reported outcomes.

The lack of effective long-term control of eosinophilic esophagitis (EoE) highlights the unmet need for targeted systemic therapies.

Other gastrointestinal disorders and inflammatory diseases have also been linked to psychiatric disorders, but not much is known about the connection to eosinophilic esophagitis (EoE).

The study was conducted because information on the relationship between eosinophilic esophagitis (EOE) symptoms and biologic findings are limited, so researchers looked at the long-term effects of esophageal dilation, including patient-reported outcome (PRO) measures.

Reduced health-related quality of life was identified in patients with chronic rhinosinusitis with nasal polyps compared with the general population—regardless of previous sinus surgery or presence of comorbidities.

Across 3 disease states, dupilumab has been shown to create rapid, clinically meaningful responses that were sustained, which could improve adherence and the patient-provider relationship.

Circulating B cell–activating factor was shown to be a potential biomarker in identifying blood eosinophil counts and risk of postoperative nasal polyp recurrence among patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Recent clinical trials have excluded older patients with eosinophilic esophagitis (EoE) from participating; however, patients aged 65 years and older are more likely to respond to topical corticosteroids than their younger counterparts.

Young adult men with chronic rhinosinusitis with nasal polyps were shown to be at greater risk of nasal polyp recurrence after endoscopic sinus surgery than elderly men and adult women of all ages.

A recent study found a correlation in patients with an IgE-mediated food allergy (IgE-FA) reporting symptoms of eosinophilic esophagitis (EoE), leading researchers to conclude screening for EoE may be beneficial.

A child’s schooling is affected by the impact of eosinophilic esophagitis (EoE), explained Colette Romero, whose son has the disease.

A significantly greater proportion of patients with chronic rhinosinusitis with nasal polyps reported symptom-free days for at least 1 symptom when treated with dupilumab vs placebo in the 28 days preceding 24-week and 52-week analysis intervals.

Younger and older patients with noneosinophilic chronic rhinosinusitis (CRS) with nasal polyps showed significant differences in preoperative blood eosinophil levels and postoperative modified Lund-Kennedy scores.

A case report describes how an eosinophilic esophagitis diagnosis does not preclude other eosinophilic gastrointestinal diseases from developing.

A comparison of type 2 biologics indicated for the treatment of chronic rhinosinusitis with nasal polyps identified dupilumab as the most effective drug in decreasing nasal polyp score and nasal congestion severity, whereas benralizumab was least effective.